15 CROSBY DRIVE, BEDFORD, MA
Ocular Therapeutix to Present SOL-1 Trial Results at Macula Society Meeting
Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
CFO Departure - Donald Notman Takes Medical Leave; Jason Robins Appointed Int...
Other Events
Reports Third Quarter 2025 Financial Results and Business Highlights
Announces Pricing of Underwritten Offering of Common Stock
FY 2024
Q3
Q2
Q1
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement